BOSTON– Alloy Therapeutics Inc., a biotechnology ecosystem company focused on expanding access to advanced drug discovery technologies, has announced a collaboration with the University of British Columbia (UBC) to accelerate the discovery of novel antibody therapeutics for pandemic preparedness.
Under the partnership, Alloy will provide its antibody discovery expertise to support UBC’s research into infectious-disease targets. UBC scientists will employ high-throughput cryo-electron microscopy (cryo-EM) to design and refine antibody candidates as part of the Pathogen Response Optimization by Generating Therapeutics Rationally (PROGENITER) program. The initiative is part of Canada’s Immuno-Engineering and Biomanufacturing Hub (CIEBH), one of five national research hubs created to strengthen the country’s readiness for current and future pandemic threats.
“This collaboration between UBC and Alloy brings together complementary expertise that will accelerate our mission to develop technologies capable of rapidly generating novel antibody therapies,” said Sriram Subramaniam, Ph.D., PROGENITER Director and Gobind Khorana Canada Excellence Research Chair at UBC. “By combining UBC’s cryo-EM capabilities with Alloy’s antibody discovery platforms, we’re building a powerful foundation for innovation in therapeutic development.”
Heather Schwoebel, Chief Business Officer, Antibodies, and Head of Strategic Collaborations at Alloy Therapeutics, added, “We’re proud to partner with UBC in supporting Canada’s pandemic preparedness efforts. This collaboration highlights Alloy’s commitment to working flexibly with global research partners to advance science and create value for the broader biomedical community.”
John-Paul Heale, M.B.A., Ph.D., Managing Director of Innovation UBC, said, “Alloy’s partnership with UBC strengthens the PROGENITER program and reflects our shared goal of accelerating scientific discovery through open, collaborative partnerships that deliver real-world impact.”
As part of the collaboration, Alloy has also established a subsidiary in Ontario, Canada, expanding its international footprint and reinforcing its long-term commitment to global collaboration in drug discovery.
